Daniel Saidian MD

Lucky husband & father, eager urologist practicing prostate cancer focal therapy, health-tech enthusiastic

[Daniel Saidian MD @DanielSaidian]

@LondonProstate1 @IP_London @imperialurology @FocalSociety @BSoT_UK @Uroweb @EAUrf @EAUYAUrology @eau_yuo @EAU_YAUroTech @USANZUrology @urologytraining And of course, Allready established a new focal therapy program in my homeland hospital (Meir, Israel) with great success. doing LATP BXs, cryos, rezum, pending for hifu soon.
Still in touch and getting big support from prof. Ahmed, Mr Arya and Mr Shah 💖

[Scott Eggener @uroegg]

First ever locally injectable immunoactive agent with proven DFS benefit in localized prostate cancer.

Tandem randomized Phase II in surveillance forthcoming.

Origin: Baylor basic science lab (support research!)

https://t.co/gGOjo9eMa5

[NEJM @NEJM]

Presented at #ASCO26:

In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: https://t.co/UxXUkYwd8Z

Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer https://t.co/XgeWL3lqy6

@ASCO

[Yüksel Ürün @DrYukselUrun]

Excellent discussion by @declangmurphy on a post-PROTEUS algorithm for high-risk prostate cancer.
Selection is becoming the new treatment frontier.

#ASCO26 @gu_onc
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

[[email protected] @danielkeizman]

Was glad to orally present today at #ASCO2026 our study
revealing that #decipher Genomic classifier has distinct transcriptomic signatures in reclassified early #prostatecancer

Thank you @TamarZahavi @YoavManaster @Davicioni

https://t.co/XNDqvQQ4i8

@Veracyte
@ASCO

[Adam B. Weiner, MD @Adam_Weiner535]

🚨 PROTEUS: perioperative apalutamide moves into high-risk localized #prostatecancer

Just out in @NEJM

🧬 2109 men w/ high-risk localized or locally advanced PCa randomized to ADT + apalutamide vs ADT + placebo around radical prostatectomy.

🎯 Both stated primary endpoints met.

⚠️ But the trial deserves nuance. Thread 🧵

#ASCO26 @ASCO @PCF_Science

[Luis G. Medina @LuisMedinaMD]

Partial gland ablation for radio-recurrent localized prostate cancer

Interesting initial series evaluating short-term oncological and functional outcomes after salvage HIFU and cryotherapy.

Great team led by @ALDCAbreu and @KanekoMasatomo

➡️ https://t.co/iNMVVMlN2s

@lorenzormc @emory_urology @EmoryUroOnc @USC_Urology @MUSC_UroOnc @RSanchez_Salas @FocalSociety @MUSC_UroOnc @SUO_YUO @ResidentesCAU @kevinchua_

[Katy Beckermann @katy_beckermann]

Cochrane updated its PSA screening meta-analysis. 789,086 men across 6 RCTs.

➡️ PCa-specific mortality: rate ratio 0.87 (moderate certainty)

➡️ Metastatic diagnosis: RR 0.65

➡️ Adverse events / QoL: little to no difference

Why this matters: 💡 PSA screening is back on stronger evidentiary footing for disease-specific mortality. Shared decision making still drives the recommendation downstream and additional tools (biomarkers and MRI) continue to improve the gap.

https://t.co/VZk9tKRW0V

@EBMUrology #ProstateCA #Screening #Cochrane #GUonc #AUA26

[Daniel Saidian MD @DanielSaidian]

@MayoUrology @MayoClinic @LondonProstate1 @IP_London Definitely the best, great honour for both sides💪

[Daniel Saidian MD @DanielSaidian]

@LondonProstate1 @DerekLomas @SBoorjian Congratulations dear prof ❤️ well deserved 👏

[Alastair Lamb @LambAlastair]

This was quite distressing. Two #RARP in a row for GG1 #prostatecancer...
Realise it's a technique session.
But surely we can't ignore poor decision-making?
Dr Kocher:
"Good surgeon knows how to operate; excellent surgeon knows when (not) to operate"
But the crowd want it!
#AUA26

[Tuğba Başoğlu, MD @tugbawitter]

BRCA1/2 may be telling us a bigger story.

A new ESMO Open study suggests that pathogenic BRCA1/2 variants may increase the risk of less common cancers beyond breast, ovarian, pancreatic, and prostate cancer.

Signals observed:

BRCA1 → thyroid cancer
BRCA2 → bladder, head & neck, and skin cancers
The most striking finding:
BRCA2-associated bladder cancer risk appeared particularly high in females.

These data are hypothesis-generating, but they may reshape how we think about hereditary cancer predisposition and precision oncology.
#BRCA #PrecisionOncology #CancerGenetics #Oncology
@ESMO_Open @OncoAlert

[Adam B. Weiner, MD @Adam_Weiner535]

🚨Testosterone replacement therapy after surgery for #prostatecancer🚨

@JAMAInternalMed

⭐️SPIRIT trial

📊 RCT, n=136, low/int-grade PCa, post-RP, hypogonadal men
⏱️ TRT started ≥2 yrs post-RP w/ undetectable PSA
💉 12 wks testosterone vs placebo
✅ ↑ sexual activity (+0.9 events/day), desire, lean mass, VO₂ peak
🛡️ ZERO biochemical recurrences

⚠️ Short-term, proof-of-concept.
👉Bigger/longer trials including patients with higher-risk disease needed

@PCFnews @PCF_Science @urotoday @renalandurology @UrologyTimes

🔗https://t.co/nPtK3EahPQ

[NEJM @NEJM]

New in our partnership with @DGlaucomflecken: the KEYNOTE-905 trial evaluated enfortumab vedotin plus pembrolizumab as perioperative therapy in patients with muscle-invasive bladder cancer who were ineligible to receive cisplatin. Read the full study for free: https://t.co/A1RikB7ZIo

[European Urology @EUplatinum]

📢 New publication in European Urology

We are pleased to highlight a new study published in European Urology, titled “IP8-FLUORESCE: A Prospective Paired Cohort Study Evaluating the Diagnostic Accuracy of Fluorescence Confocal Microscopy for Real-time Assessment of Surgical Margins in Radical Prostatectomy”.

👏 Congratulations to @NikhilMayor, @AJWLight, and Matt Winkler on this excellent contribution, together with all co-authors.

🔗 Read the full article here:
👉 https://t.co/bS80NR4Qtk

#EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology

[European Urology Oncology @EurUrolOncol]

"Management of local prostate cancer (PCa) recurrence after primary radiotherapy (RT) remains challenging in daily practice. Salvage high-intensity focused ultrasound (S-HIFU) represents a valid option, but large prospective data are missing. "

Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study) by Guillaume Ploussard et al

Read the full article: https://t.co/sp4wWAuHpL

We thank the authors for trusting EUO to publish their work!

@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

[Daniel Saidian MD @DanielSaidian]

@MUSC_UroOnc 2% utis after tp bxs.?? These are TR numbers, something is wrong..

[Emre Yekedüz @yekeduz_emre]

A @JAMAOnc paper by Marcin Miszczyk et al. :
Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis

doi: 10.1001/jamaoncol.2026.1023
@OncoAlert #cancer #oncology

[Dra. María Natalia Gandur Quiroga @nataliagandur]

⭐ Expanding theranostic targets in prostate cancer — beyond tumor cells

@OncoAlert @APCCC_Lugano
#IPCS26 #APCCC26 @Silke_Gillessen @AOmlin
🔹 Next-generation targeting strategies are redefining the field

🔹 Key insights:
• GRPR emerges as a relevant target → especially in PSMA-low disease
• DLL3 opens a new avenue in NEPC-directed theranostics
• Clear movement toward phenotype-driven target selection
• Tumor microenvironment is now actionable → FAP as a stromal target
• FAP targeting may help overcome tumor heterogeneity and resistance

🔹 Take-home:
We are no longer targeting just the tumor —
we are targeting the ecosystem (tumor + phenotype + microenvironment)
@ProfKHerrmann @DrMHofman @EAntonarakis @DrYukselUrun
#ProstateCancer #UroOncology #Oncology

[Adam B. Weiner, MD @Adam_Weiner535]

🎧 Music during prostate biopsy = real clinical impact

🚨VIVALDI RCT in @EurUrolOpen

✅Patient-selected music during transperineal prostate biopsy lead to....

↓ Pain at every step (VAS consistently lower)
↓ Anxiety & distress post-procedure
↓ Sedation needs (37% vs 57%)
↑ Patient satisfaction & willingness to repeat

🫰Simple. Scalable. Zero downside.

⭐️So critical for anyone with a large Active Surveillance population

💡Nonpharmacologic interventions aren’t “soft”—they’re effective.

🔗https://t.co/0eicfj7Vxz

@PCFnews @PCF_Science @EUplatinum

[Dra. María Natalia Gandur Quiroga @nataliagandur]

⭐ Are we overtreating patients in the mpMRI / PSMA PET era?

@OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin

Presented by Derya Tilki

🔹 Excellent overview on the strengths and limits of modern imaging

🔹 Key messages:
🔹 1. MRI-derived EPE and seminal vesicle invasion are independently associated with biochemical recurrence and metastatic failure
🔹 2. MRI-based T-staging remains clinically useful — but terminology and reporting need standardization
🔹 3. PSMA PET/CT improves detection of local tumor extension and nodal disease in selected settings
🔹 4. Combining mpMRI + PSMA PET may better define dominant and non-dominant lesions
🔹 5. Imaging–biopsy discordance remains a key challenge in treatment planning
🔹 6. More accurate imaging can improve selection — but may also increase the risk of overtreatment if not interpreted carefully
🔹 Take-home:
Modern imaging should refine decisions, not replace clinical judgment, pathology and multidisciplinary discussion.
@declangmurphy @RenuEapen @DrYukselUrun @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @Uromigos @EUplatinum @EANM_NucMed @ESTRO_RT @Uroweb